# US 8,278,320 B2 · Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,320 B2
- Document ID: US8278320B2
- Status: Granted
- Kind: B2
- Application number: 12/907,122
- Filed: 2010-10-19
- Published: 2011-10-27
- Granted: 2012-10-02
- Earliest claimed: 2009-10-28
- Assignees: Bristol-Myers Squibb Company
- Inventors: Ivar M. McDonald; Robert A. Mate; James H. Cook, II; Dalton King; Richard E. Olson; Nenghui Wang; Christiana I. Iwuagwu; F. Christopher Zusi; Matthew D. Hill; Haiquan Fang; John E. Macor
- Web page: https://patentgrep.com/patent/US8278320B2

## CPC

- C07D 498/20: Spiro-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

## Claims

### Claim 1

A compound of formula I, or a stereoisomer thereof,
wherein
R1 is selected from the group consisting of isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, quinazolinyl, naphthyridinyl, indazolyl, indolyl, 2-indolonyl, benzisoxazolyl, benzoisothiazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, furopyridinyl, thienopyridinyl, thienopyrimidinyl, isothiazolopyridinyl, thiazolopyridinyl, thiazolopyridinonyl, thiazolopyrazinyl, thiazolopyrimidinyl, triazolopyridinyl, triazolopyrazinyl, pyrrolotriazinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5H-chromeno[4,3-d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[d]pyrimidinyl, 5,6,7,8-tetrahydroquinazolinyl, 7,8-dihydroquinazolin-5(6H)-onyl, and tetrahydrobenzothiazolyl, and is substituted with 0-3 substituents independently selected from the group consisting of C1-4alkyl, C3-7cycloalkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, C3-7cycloalkoxy, C1-4-alkylthio, phenoxy, benzyloxy, halo, hydroxy, cyano, nitro, C1-4alkylsulfonyl, NR2R3, pyrrolidinonyl, methylenedioxy, furyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, triazolyl, pyrazinyl, pyrimidinyl, naphthyl, C1-4alkylamido, CONR2R3, pyridyl, phenyl, and benzyl, and where imidazolyl, pyridyl, phenyl and benzyl are substituted with 0-2 substituents independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, C1-4haloalkyl, C1-4haloalkoxy, and NR2R3;
R2 is hydrogen, C1-4alkyl, C1-4hydroxyalkyl, or C1-4aminoalkyl;
R3 is hydrogen, C1-4alkyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; or R2 and R3 taken together with the nitrogen atom to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N—(C1-4alkyl)piperazinyl, morpholinyl, or homopiperidinyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1 where R1 is selected from the group consisting of dimethylisoxazolyl, (methyl)(phenyl)isoxazolyl, methylpyrazolyl, dimethylpyrazolyl, thienylpyrazolyl, methoxyphenylpyrazolyl, thiazolyl, bromothiazolyl, cyanothiazolyl, methylthiazolyl, dimethylthiazolyl, (methyl)(phenyl)thiazolyl, isopropylthiazolyl, butylthiazolyl, benzylthiazolyl, methoxyphenylmethylthiazolyl, phenylthiazolyl, chlorophenylthiazolyl, methoxyphenylthiazolyl, (methoxyphenyl)(methyl)thiazolyl, pyridinylthiazolyl, (phenyl)(methyl)imidazolyl, methyloxadiazolyl, ethyloxadiazolyl, methylthiadiazolyl, fluorophenylthiadiazolyl, furylthiadiazolyl, (dimethylcarboxamido)(methyl)thiazolyl, (pyrrolidinylCO)thiazolyl, phenyltriazolyl, pyridinyl, bromopyridinyl, chloropyridinyl, (chloro)(fluoro)pyridinyl, (chloro)(methyl)pyridinyl, dichloropyridinyl, fluoropyridinyl, cyanopyridinyl, (cyano)(methyl)pyridinyl, (cyano)(dimethyl)pyridinyl, methoxypyridinyl, (methylpyrrolidinyl)pyridinyl, phenylpyridinyl, methoxypyridinylpyridinyl, pyridazinyl, bromopyridazinyl, chloropyridazinyl, methylpyridazinyl, methoxypyridazinyl, methylthiopyridazinyl, pyrrolidinylpyridazinyl, pyrrolidinonylpyridazinyl, phenylpyridazinyl, pyridinylpyridazinyl, methoxypyridinylpyridazinyl, pyrimidinyl, (bromo)(isopropyl)pyrimidinyl, (bromo)(dimethyl)pyrimidinyl, (bromo)(cyclopropyl)pyrimidinyl, (bromo)(methoxy)pyrimidinyl, (bromo)(phenyl)pyrimidinyl, (bromo)(pyridinyl)pyrimidinyl, chloropyrimidinyl, (chloro)(dimethyl)pyrimidinyl, (methyl)(methoxy)pyrimidinyl, methylpyrimidinyl, ethylpyrimidinyl, (methyl)(phenyl)pyrimidinyl, dimethylpyrimidinyl, butylpyrimidinyl, isopropylpyrimidinyl, cyclopropylpyrimidinyl, methoxypyrimidinyl, dimethoxypyrimidinyl, isopropoxypyrimidinyl, cyclopentoxypyrimidinyl, difluoromethoxypyrimidinyl, trifluoroethoxypyrimidinyl, phenoxypyrimidinyl, methylthiopyrimidinyl, phenylpyrimidinyl, chlorophenylpyrimidinyl, methylphenylpyrimidinyl, methoxyphenylpyrimidinyl, (phenyl)(triazolyl)pyrimidinyl, pyridinylpyrimidinyl, methoxypyridinylpyrimidinyl, methoxypyrimidinylpyrimidinyl, naphthylpyrimidinyl, pyrazinyl, bromopyrazinyl, (bromo)(methoxy)pyrazinyl, chloropyrazinyl, methylpyrazinyl, dimethylpyrazinyl, butylpyrazinyl, cyanopyrazinyl, methoxypyrazinyl, isopropoxypyrazinyl, trifluoromethylpyrazinyl, and phenylpyrazinyl, and dimethyltriazinyl;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of claim 1 where R1 is selected from the group consisting of dimethylpyridinoisoxazolyl, benzoxazolyl, chlorobenzoxazolyl, fluorophenylbenzoxazolyl, ethylphenylbenzoxazolyl, dimethylaminophenylbenzoxazolyl, pyridinylbenzoxazolyl, benzothiazolyl, acetamidobenzothiazolyl, bromobenzothiazolyl, chlorobenzothiazolyl, (chloro)(methyl)benzothiazolyl, (chloro)(methoxy)benzothiazolyl, fluorobenzothiazolyl, difluorobenzothiazolyl, cyanobenzothiazolyl, methylbenzothiazolyl, dimethylbenzothiazolyl, (methyl)(methoxy)benzothiazolyl, ethylbenzothiazolyl, trifluoromethylbenzothiazolyl, hydroxybenzothiazolyl, methoxybenzothiazolyl, ethoxybenzothiazolyl, isopropoxybenzothiazolyl, trifluoromethoxybenzothiazolyl, difluoromethoxybenzothiazolyl, dimethoxybenzothiazolyl, morpholinylbenzothiazolyl, (pyrrolidinylCO)benzothiazolyl, methylsulfonylbenzothiazolyl, thiazolopyridinyl, chlorothiazolopyridinyl, dimethylthiazolopyridinyl, benzyloxythiazolopyridinyl, difluoromethoxythiazolopyridinyl, benzotriazolyl, indolonyl, indazolyl, bromoindazolyl, chloroindazolyl, fluoroindazolyl, (methyl)(methoxy)indazolyl, methoxyindazolyl, trifluoromethylindazolyl, trifluoromethoxyindazolyl, difluoromethoxyindazolyl, benzimidazolyl, fluorobenzimidazolyl, methylbenzimidazolyl, (methyl)(methoxy)benzimidazolyl, methoxybenzimidazolyl, tetrahydrobenzothiazolyl, furopyridinyl, dimethylfuropyrimidinyl, thienopyrimidinyl, isopropylthienopyrimidinyl, dimethylthienopyrimidinyl, chlorotriazolopyridinyl, methyltriazolopyridinyl, trifluoromethyltriazolopyridinyl, methoxytriazolopyridinyl, triazolopyrazinyl, bromopyrrolotriazinyl, dimethylaminothiazolopyrimidinyl, thiazolopyazinyl, bromothiazolopyazinyl, methoxythiazolopyazinyl, methylthiothiazolopyazinyl, methoxythiazolopyrimidinyl, (methyl)(methoxy)thiazolopyrimidinyl, quinolinyl, bromoquinolinyl, fluoroquinolinyl, methylquinolinyl, (methyl)(methoxy)quinolinyl, isoquinolinyl, bromoisoquinolinyl, dichloroisoquinolinyl, methylisoquinolinyl, dimethylisoquinolinyl, quinoxalinyl, chloroquinoxalinyl, methylquinoxalinyl, methoxyquinoxalinyl, quinazolinyl, bromoquinazolinyl, naphthyridinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5H-chromeno[4,3-d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[d]pyrimidinyl, 5,6,7,8-tetrahydroquinazolinyl, and 7,8-dihydroquinazolin-5(6H)-onyl;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of claim 1 where R1 is selected from the group consisting of dichloropyridinyl, methoxypyridinyl, methoxypyrimidinyl, phenylpyrimidinyl, (methylphenyl)pyrimidinyl, pyridinylpyrimidinyl, chloropyrazinyl, benzothiazolyl, methoxybenzothiazolyl, thiazolopyridinyl, chlorothiazolopyridinyl, fluorothiazolopyridinyl, methoxythiazolopyridinyl, and isoquinoinyl; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A compound of claim 1 where R1 is selected from the group consisting of imidazolylpyrimidinyl, (chloroimidazolyl)pyrimidinyl, (triazolyl)pyrimidinyl, (methylimidazolyl)pyrimidinyl, (methoxy)(pyrrolidinyl)pyrimidinyl, benzo[e][1,2,4]triazinyl, chlorobenzoxazolyl, pyrrolo[1,2-f][1,2,4]triazinyl, thieno[3,2-d]pyrimidinyl, methylthieno[3,2-d]pyrimidinyl, and methylbenzoxazolyl; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The stereoisomer of claim 1 according to Formula Ic;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The stereoisomer of claim 1 according to Formula Id;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6, 7)

A compound of claim 6 or 7 where R1 is selected from the group consisting of dichloropyridinyl, methoxypyridinyl, methoxypyrimidinyl, phenylpyrimidinyl, (methylphenyl)pyrimidinyl, pyridinylpyrimidinyl, chloropyrazinyl, benzothiazolyl, methoxybenzothiazolyl, thiazolopyridinyl, chlorothiazolopyridinyl, fluorothiazolopyridinyl, methoxythiazolopyridinyl, and isoquinoinyl; or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 6, 7)

A compound of claim 6 or 7 where R1 is selected from the group consisting of imidazolylpyrimidinyl, (chloroimidazolyl)pyrimidinyl, (triazolyl)pyrimidinyl, (methylimidazolyl)pyrimidinyl, (methoxy)(pyrrolidinyl)pyrimidinyl, benzo[e][1,2,4]triazinyl, chlorobenzoxazolyl, pyrrolo[1,2-f][1,2,4]triazinyl, thieno[3,2-d]pyrimidinyl, methylthieno[3,2-d]pyrimidinyl, and methylbenzoxazolyl; or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 6, 7)

A compound of claim 6 or 7 where R1 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolopyridinyl, isoquinolinyl, and benzoxazolyl, and is substituted with 0-3 substituents independently selected from the group consisting of C1-4alkyl, C3-7cycloalkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, C3-7cycloalkoxy, halo, hydroxy, cyano, NR2R3, pyrrolidinonyl, methylenedioxy, furyl, thienyl, triazolyl, imidazolyl, thiazolyl, oxazolyl, pyrimidinyl, naphthyl, C1-4alkylamido, CONR2R3, pyridyl, and phenyl, and where pyridyl, phenyl, thiazolyl and imidazolyl are substituted with 0-2 substituents independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, C1-4haloalkyl, C1-4haloalkoxy, and NR2R3; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A compound of claim 1 selected from the group consisting of (3R*,4S*)—N-(6-methoxybenzo[d]thiazol-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(6-methoxybenzo[d]thiazol-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(5-chlorothiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(5-fluorothiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-4′-H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(3,5-dichloropyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(isoquinolin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(isoquinolin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3S,4S)—N-(isoquinolin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine amine, (3S,4S)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4R*)—N-(5-m-tolylpyrimidin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*, 4R*)—N-(5-methoxypyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-(pyridin-3-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(benzo[d]thiazol-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-methoxypyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(5-chloropyrazin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(4-phenylpyrimidin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4S*)—N-(isoquinolin-3-yl)-4′-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3S,4R)—N-(isoquinolin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R*,4S*)—N-(isoquinolin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, afford (3R*,4S*)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3S,4R)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, and (3R,4S)—N-(thiazolo[5,4-b]pyridin-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A compound of claim 1 selected from the group consisting of (3R,4R)—N-(6-(pyridin-4-yl)pyrimidin-4-yl)-4H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-(1H-imidazol-1-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-(4-chloro-1H-imidazol-1-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(5-methoxy-6-(pyrrolidin-1-yl)pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(benzo[e][1,2,4]triazin-3-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(5-chlorobenzo[d]oxazol-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(pyrrolo[1,2-f][1,2,4]triazin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(thieno[3,2-d]pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, (3R,4R)—N-(7-methylthieno[3,2-d]pyrimidin-4-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine, and (3R,4R)—N-(6-methylbenzo[d]oxazol-2-yl)-4′H-1-azaspiro[bicyclo[2.2.1]heptane-3,5′-oxazol]-2′-amine; or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method for the treatment of schizophrenia which comprises administering to a patient a therapeutically affective amount of a compound of claim 1.
